CM
CRSP icon

Caption Management’s CRISPR Therapeutics CRSP Stock Holding History

Caption Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.07M Sell
43,500
-413,600
-90% -$21.8M 0.01% 820
2025
Q4 		$24M Buy
457,100
+3,500
+0.8% +$210K 0.16% 139
2025
Q3 		$29.4M Buy
453,600
+220,800
+95% +$12.7M 0.23% 90
2025
Q2 		$11.3M Buy
232,800
+89,200
+62% +$3.45M 0.13% 178
2025
Q1 		$4.89M Buy
143,600
+43,000
+43% +$1.82M 0.05% 400
2024
Q4 		$3.96M Buy
+100,600
New +$4.75M 0.04% 446
2024
Q3 		– Sell
-135,000
Closed -$7.29M – 1344
2024
Q2 		$7.29M Sell
135,000
-250,000
-65% -$14.5M 0.11% 192
2024
Q1 		$26.2M Sell
385,000
-195,700
-34% -$14M 0.4% 49
2023
Q4 		$36.4M Buy
580,700
+483,400
+497% +$26.7M 0.49% 31
2023
Q3 		$4.42M Sell
97,300
-63,000
-39% -$3.25M 0.07% 351
2023
Q2 		$9M Buy
+160,300
New +$9.1M 0.16% 159
2023
Q1 		– Sell
-25,000
Closed -$1.02M – 1173
2022
Q4 		$1.02M Sell
25,000
-40,000
-62% -$2.12M 0.02% 747
2022
Q3 		$4.25M Buy
65,000
+5,000
+8% +$362K 0.06% 394
2022
Q2 		$3.65M Buy
60,000
+40,000
+200% +$2.35M 0.05% 469
2022
Q1 		$1.26M Buy
20,000
+5,000
+33% +$314K 0.02% 889
2021
Q4 		$1.14M Buy
+15,000
New +$1.31M 0.01% 997
2021
Q3 		– Sell
-39,900
Closed -$6.46M – 1557
2021
Q2 		$6.46M Sell
39,900
-2,600
-6% -$316K 0.08% 308
2021
Q1 		$5.18M Buy
+42,500
New +$6.42M 0.11% 236
2020
Q3 		– Sell
-45,000
Closed -$3.31M – 1063
2020
Q2 		$3.31M Sell
45,000
-55,000
-55% -$3.22M 0.11% 252
2020
Q1 		$4.24M Hold
100,000
– – 0.24% 120
2019
Q4 		$6.09M Buy
+100,000
New +$5.46M 0.2% 129
2018
Q4 		– Sell
-9,400
Closed -$417K – 488
2018
Q3 		$417K Hold
9,400
– – 0.02% 429
2018
Q2 		$553K Buy
+9,400
New +$536K 0.04% 311

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caption Management's CRSP Position: Q2 2025 in Review

Caption Management sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 3,383 shares — an estimated $131K sold.

Caption Management first reported a position in CRSP in Q2 2018 and held it in 7 quarters. The position peaked at $1.3M in Q2 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Caption Management reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 3,383 CRISPR Therapeutics shares in Q2 2025, an estimated $131K.
  • Caption Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 7 quarters.
  • Caption Management's CRISPR Therapeutics position peaked at $1.3M in Q2 2024.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.